SHM VTE Prevention CollaborativeGet tools
and long-term mentoring support to decrease your patients' incidence of
preventable hospital acquired VTE. Read below to find out how to
participate. SHM's mentored implementation programs- BOOST,
GCMI and VTE-PC- are now approved through ABIM for 20 points towards the
Self-Evaluation of Practice Performance requirement of Maintenance of
Certification (MOC). Click here for more
information. What
is Mentored Implementation? The Problem of
Hospital-acquired Venous Thromboembolism (VTE)Venous
thromboembolic disease, ranging from asymptomatic deep vein thrombosis
(DVT) to massive pulmonary embolism (PE), is a significant cause of
morbidity and mortality in hospitalized patients. Almost all
hospitalized patients are at risk for VTE and the literature suggests
that approximately half of all VTE's are
hospital-acquired.1-4 PE is recognized as the cause of death
for more than 100,000 hospitalized patients in the Unites States every
year, and is considered a contributing factor in the death of 100,000
more patients.1
Multiple clinical trials have provided irrefutable evidence that primary
thromboprophylaxis reduces the incidence of DVT and PE.5
Unfortunately, numerous studies have also shown that the majority of
hospitalized patients with risk factors for DVT do not receive
appropriate prophylaxis.6-8 Hospitalists are ideally
positioned to reduce the incidence of preventable VTE's, both by using
known best-practices to improve care delivered to their own patients,
and, more importantly, by leading hospital-wide QI efforts that improve
care for all patients at their home institutions.
The VTE
PC ProgramSHM mentors with VTE and QI expertise will provide
participants with practical assistance on topics central to designing,
evaluating, implementing and sustaining a VTE prevention program.
Participants will receive assistance with: - Securing
institutional support for the project
- Assembling and leading the
project team
- Developing goals and aims for the
project
- Mapping the current processes for assessing VTE and
bleeding risk and administering prophylaxis
- Evaluating the
evidence and incorporating it into local risk assessment and prophylaxis
recommendations
- Redesigning care delivery processes to include
high-reliability features that promote adherence to best
practices
- Developing and implementing educational/outreach plans
to ensure buy-in from key stakeholders
- Collecting, analyzing and
reporting outcome data
- Identifying patients appropriate for
post-discharge prophylaxis and exploring processes for ensuring
continued administration of appropriate prophylaxis
Mentors
will work with each participant to tackle site-specific issues using
proven QI techniques. Mentoring will occur during scheduled telephone
calls offered over a 15-18 month period. Instruction will be organized
around the VTE QI Implementation Guide, SHM's step-by-step
guide for developing a VTE prevention program. (The Workbook can be
viewed and downloaded from the VTE
Resource Room.)  Applying to
the ProgramsCurrently, we are not accepting applications for the
VTE Prevention Collaborative. Please check back for future Mentored
Implementation opportunities. For further information about the
VTE Prevention Collaborative program, please contact Wendy Nickel, at
wnickel@hospitalmedicine.org
or 267-702-2678.
References1. Goldhaber SZ, Tapson VF. A prospective
registry of 5,451 patients with ultrasound-confirmed deep vein
thrombosis. Am J Cardiol 2004;93(2):259-62.
2. Task Force on Pulmonary Embolism ESoC. Guidelines on diagnosis and
management of acute pulmonary embolism. [see comments]. European
Heart Journal 2000;21(16):1301-1336.
3. Stein PD, Huang H, Afzal A, Noor HA. Incidence of acute pulmonary
embolism in a general hospital: Relation to age, sex, and race. Chest
1999;116(4):909-913.
4. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton
LJr. Trends in the incidence of deep vein thrombosis and pulmonary
embolism: A 25-year population-based study. Arch Intern Med
1998;158:585-593.
5. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray
JG. Prevention of venous thromboembolism: The seventh ACCP conference on
antithrombotic and thrombolytic therapy. Chest 2004;126(3
Suppl):338S-400S.
6. Stratton MA, Anderson FA, Bussey HI, Caprini J, Comerota A, Haines
ST, Hawkins DW, O'Connell MB, Smith RC, Stringer KA. Prevention of
venous thromboembolism: Adherence to the 1995 american college of chest
physicians consensus guidelines for surgical patients. Arch Intern Med
2000;160(3):334-40.
7. Anderson FA, Jr., Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A,
Patwardhan NA. Changing clinical practice. Prospective study of the
impact of continuing medical education and quality assurance programs on
use of prophylaxis for venous thromboembolism. Arch Intern Med
1994;154(6):669-77.
8. Walker A, Campbell S, Grimshaw J. Implementation of a national
guideline on prophylaxis of venous thromboembolism: A survey of acute
services in Scotland. Thromboembolism prevention evaluation study group.
Health Bull (Edinb) 1999;57(2):141-7. Privacy
Policy This project is supported in part by
funding from sanofi-aventis US,
LLC |
Home 
